Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Transcode Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 9 | 8 | −1 |
| Shares | 30.4K | 14.4K | −16.0K (−52.5%) |
| Value | $237.0K | $155.0K | −$82.0K (−34.6%) |
New holders (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 11,702 | $125.8K | 0.01% |
| Citigroup Inc | 1,586 | $17.0K | 0.00% |
| Federation des caisses Desjardins du Quebec | 975 | $10.5K | 0.00% |
Sold out (4)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Goldman Sachs Group Inc | 28,042 | $218.7K |
| UBS Group AG | 1,432 | $11.2K |
| South State Corp. | 482 | $3.76K |
| FMR LLC | 3 | $23 |